| Pharmacokinetics and safety of 3 months of weekly rifapentine and isoniazid for tuberculosis prevention in pregnant women JS Mathad, R Savic, P Britto, P Jayachandran, L Wiesner, G Montepiedra, ... Clinical Infectious Diseases 74 (9), 1604-1613, 2022 | 22 | 2022 |
| Evaluating within‐subject variability for narrow therapeutic index drugs P Jayachandran, H Okochi, LA Frassetto, W Park, L Fang, L Zhao, ... Clinical Pharmacology & Therapeutics 105 (2), 411-416, 2019 | 13 | 2019 |
| Characterizing HIV-preventive, plasma tenofovir concentrations—a pooled participant-level data analysis from human immunodeficiency virus preexposure prophylaxis clinical trials M Garcia-Cremades, K Vučićević, CW Hendrix, P Jayachandran, ... Clinical Infectious Diseases 75 (11), 1873-1882, 2022 | 12 | 2022 |
| Results from a phase 1 study of sodium selenite in combination with palliative radiation therapy in patients with metastatic cancer SJ Knox, P Jayachandran, CA Keeling, KJ Stevens, N Sandhu, ... Translational oncology 12 (11), 1525-1531, 2019 | 7 | 2019 |
| Batch‐to‐Batch and Within‐Subject Variability: What Do We Know and How Do These Variabilities Affect Clinical Pharmacology and Bioequivalence? LZ Benet, P Jayachandran, KJ Carroll, E Burmeister Getz Clinical Pharmacology & Therapeutics 105 (2), 2019 | 7 | 2019 |
| Clinical pharmacokinetics of oral sodium selenite and dosing implications in the treatment of patients with metastatic cancer P Jayachandran, SJ Knox, M Garcia-Cremades, RM Savić Drugs in R&D 21, 169-178, 2021 | 6 | 2021 |
| Diversity in clinical pharmacology: a call to action K Brown, S Etrouth, P Jayachandran, J Moore, A Oni‐Orisan, L Vasist, ... Clinical Pharmacology & Therapeutics 113 (3), 483-485, 2023 | 4 | 2023 |
| Subcutaneous administration of monoclonal antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development JD Davis, M Bravo Padros, DJ Conrado, S Ganguly, X Guan, HE Hassan, ... Clinical Pharmacology & Therapeutics, 2024 | 3 | 2024 |
| A Mechanistic In Vivo/Ex Vivo Pharmacokinetic‐Pharmacodynamic Model of Tenofovir for HIV Prevention P Jayachandran, M Garcia-Cremades, K Vučićević, NN Bumpus, P Anton, ... CPT: pharmacometrics & systems pharmacology 10 (3), 179-187, 2021 | 3 | 2021 |
| Disease progression modeling of the North Star Ambulatory Assessment for Duchenne Muscular Dystrophy JE Hibma, P Jayachandran, S Neelakantan, LO Harnisch CPT: Pharmacometrics & Systems Pharmacology 12 (3), 375-386, 2023 | 2 | 2023 |
| CYTOCON DB: A versatile database of human cell and molecule concentrations for accelerating model development R Desikan, P Jayachandran CPT: Pharmacometrics & Systems Pharmacology 12 (1), 5, 2023 | 1 | 2023 |
| Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure … M Garcia-Cremades, CW Hendrix, P Jayachandran, N Strydom, ... Pharmaceutics 14 (9), 1801, 2022 | 1 | 2022 |
| Role of pharmacometrics and systems pharmacology in facilitating efficient dose optimization in oncology P Jayachandran, R Desikan, S Krishnaswami, S Hennig CPT: Pharmacometrics & Systems Pharmacology, 2023 | | 2023 |
| Advances in quantitative methods and modeling for complex generic drugs and opportunities to hybridize learnings between innovator and generic drug developers P Jayachandran CPT: Pharmacometrics & Systems Pharmacology 12 (5), 549-551, 2023 | | 2023 |
